Objective. To determine the relationship between biochemical markers involved in bone turnover and bone features on imaging in knees with osteoarthritis (OA). Methods. We analyzed data from the Foundation for the National Institutes of Health OA Biomarkers Consortium within the Osteoarthritis Initiative (n 5 600). Bone marrow lesions (BMLs), osteophytes, and subchondral bone area (mm 2 ) and shape (position on 3-D vector) were assessed on magnetic resonance images, and bone trabecular integrity (BTI) was assessed on radiographs. Serum and urinary markers (serum C-terminal crosslinked telopeptide of type I collagen [CTX-I], serum crosslinked N-telopeptide of type I collagen [NTX-I], urinary NTX-I, urinary C-terminal crosslinked telopeptide of type II collagen [CTX-II], and urinary CTX-Ia and CTX-Ib) were measured. The associations between biochemical and imaging markers at baseline and over 24 months were assessed using regression models adjusted for covariates. Results. At baseline, most biochemical markers were associated with BMLs, with C statistics for the presence/absence of any BML ranging from 0.675 to 0.688. At baseline, urinary CTX-II was the marker most consistently associated with BMLs (with odds of having ‡5 subregions affected compared to no BML increasing by 1.92-fold [95% confidence interval (95% CI) 1.25, 2.96] per 1 SD of urinary CTX-II), large osteophytes (odds ratio 1.39 [95% CI 1.10, 1.77]), bone area and shape (highest partial R 2 5 0.032), and changes in bone shape over 24 months (partial R 2 range 0.008 to 0.024). Overall, biochemical markers were not predictive of changes in BMLs or osteophytes. Serum NTX-I was inversely associated with BTI of the vertical trabeculae (quadratic slope) in all analyses (highest partial R 2 5 0.028). Conclusion. We found multiple significant associations, albeit mostly weak ones. The role of systemic biochemical markers as predictors of individual bone anatomic features of single knees is limited based on our findings.
INTRODUCTION
Subchondral bone has been shown to play a pivotal role in the pathogenesis of osteoarthritis (OA) (1) . Changes in bone remodeling are frequently present early in the OA process and are associated with cartilage loss and further joint damage (2, 3) . Structural changes in the subchondral bone, such as bone marrow lesions (BMLs) and variations in bone shape, area, and trabecular texture, have been associated with incident and progressive OA and are promising targets for interventions (1, 4) . In addition, BMLs are potentially reversible and, in previous trials, reflective of the effects of interventions (5, 6) .
OA-related changes in the subchondral bone involve bone remodeling; it is intuitive to think that biochemical markers of bone turnover would also be altered in the presence of bone changes on imaging. Some biochemical markers have also been shown to be associated with OA presence, incidence, and progression (7) .
Developing a better understanding of the relationship between biochemical markers and magnetic resonance imaging (MRI) features may be advantageous for a number of reasons. First, MRI is expensive and often not readily accessible; finding a blood or urine marker that corresponds to these MRI features could enable them to be deployed to enhance clinical trial efficiency or reduce costs. Second, if there is a biochemical marker that predicts change in a bone MRI feature that ultimately becomes an intervention target, this would be helpful in the screening and potential stratification of patient phenotypes in clinical trials. However, the minimally invasive nature may be a disadvantage to using blood tests over non-contrast-enhanced MRI, which is a noninvasive imaging technique. Therefore, our aim was to assess whether or not systemic biochemical markers involved in bone remodeling are associated with the presence of structural bone features on knee OA images, including BMLs, osteophytes, subchondral bone trabecular integrity (BTI), and subchondral bone shape and area. As a secondary aim, we examined the association between biochemical markers (baseline and time-integrated concentrations [TICs] over 24 months) and changes in imaging markers over 24 months. Our study population consisted of the 600 participants included in the Foundation for the National Institutes of Health (NIH) Biomarkers Consortium OA study, a nested case-control study within the Osteoarthritis Initiative (OAI) whose aim is to investigate biologic markers involved in knee OA progression (8) .
MATERIALS AND METHODS
The OAI is a multicenter longitudinal cohort of 4,796 participants ages 45-79 years, with publicly accessible clinical, radiologic, and other data collected at baseline and at annual followup visits. We conducted an ancillary analysis of baseline and 24-month data from the Foundation for the NIH Biomarkers Consortium within the OAI (9).
Study participants. All 600 participants of the Foundation for the NIH Biomarkers Consortium OA sample were included in our study. Eligible participants (1 index knee per subject) were those with at least 1 knee with a Kellgren/ Lawrence (K/L) grade of 1, 2, or 3 at baseline (10) , assessed by central reading of standardized posteroanterior weightbearing radiographs, and availability of knee radiographs, knee MRI, stored biologic specimens, and clinical data at baseline and at 24 months. Only knees with the potential to meet criteria for radiographic and pain progression from baseline to 24 months were included (i.e., minimum medial joint space width $1.0 mm and/or Western Ontario and McMaster Universities Osteoarthritis Index pain scores #91 on a 0-100 scale at baseline). Additional criteria can be found at https://oai.epi-ucsf.org/datarelease/FNIH.asp.
Demographic and clinical data were assessed in all OAI participants at baseline. Baseline radiographs were acquired at the same time as baseline MRIs and read independently by 2 central readers for K/L grade. Radiograph reading and MRI acquisition details have been previously described (11) .
Semiquantitative MRI analysis of BMLs and osteophytes. BMLs were scored using the MRI Osteoarthritis Knee Score (MOAKS) method (12) . MOAKS uses a 4-category ordinal scale to score BML size (where grade 0 5 none, 1 5 less than 33% of subregional volume, 2 5 33-66% of subregional volume, and 3 5 greater than 66% of subregional volume), which comprises the size of ill-defined and cystic components of BMLs in 15 subregions of the knee (the medial and lateral tibiofemoral compartments [5 subregions in each], the patellofemoral compartment [4 subregions] , and the tibial subspinous region, which is associated with the insertion of the cruciate ligaments [1 subregion]). The differentiation of cystic BMLs (well-delineated
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The association between biochemical and imaging markers has not been well established in knee osteoarthritis.
We found that bone changes on imaging (i.e., bone marrow lesions, subchondral bone shape and area, osteophytes, and bone trabecular integrity) were frequently associated with biochemical markers of bone turnover, indicating a relationship with altered bone remodeling.
C-terminal crosslinked telopeptide of type II collagen was the marker most consistently associated with bone imaging features.
Based on the modest strength of associations, we do not strongly support the use of these biochemical markers as predictors for the presence of these bone imaging features in single knees.
lesions with fluid equivalent signal) versus ill-defined BMLs is part of the MOAKS but was not taken into account in our analysis, as only a minority of lesions (10.4% of all BMLs at baseline) were predominantly cystic (MOAKS scores 0 and 1) as opposed to ill-defined.
We established the maximum BML size score for the joint as the highest BML grade (ranging 0-3) across the whole knee and calculated the total number of subregions affected by any BML (total score ranging 0-15). We further categorized the number of subregions affected into 0, 1, 2, 3, 4, or $5, aiming to be consistent with the main, primary Foundation for the NIH analysis (13) .
MOAKS was also used to score osteophytes in 12 locations: patella (superior, inferior, medial, and lateral), medial and lateral femur (anterior/trochlear, posterior, and central), and the central, medial, and lateral tibia. Similar to BMLs, osteophytes were scored according to size (where 0 5 none, 1 5 small, 2 5 medium, and 3 5 large) in each subregion. For the analysis, osteophyte size was categorized as 0-1, 2, or 3, and the number of locations affected by any osteophyte across the entire knee was categorized as 0-2, 3-5, or $6.
Quantitative analysis of bone area and vector of 3-dimensional shape. Active appearance models were used to segment the bone surfaces in the medial and lateral femur, tibia, and patella. The area of subchondral bone (tAB) was analyzed in the medial and lateral compartments of the femur and tibia (mm 2 ). Bone shape was assessed by the position on 3-dimensional bone shape vectors (in normalized units, 21 is the mean shape of OA knees and 11 the mean shape for non-OA knees) in the femur, tibia, and patella. Details of the methods used to calculate the bone shape measurements can be found elsewhere (14) (15) (16) .
Radiographic analysis for the assessment of BTI. The commercially available semiautomated KneeAnalyzer software (Optasia Medical) was used to perform the radiographic fractal signature analyses of the medial tibia of knee radiographs to generate BTI parameters, as previously described (17) , with 1 modification. In slight contrast to our prior work, extraction of the BTI parameters for these analyses originated from the nadir (and center) of the fractal dimension curves, in order to reduce the correlation between the estimated parameters. The advantage of this refinement has been to create near orthogonal (nonoverlapping, independent) BTI parameters more suitable for multivariable and combinatorial statistical modeling, allowing the researcher to assess which parameter was most related to the outcomes under study. The absolute values of the parameters are therefore not directly comparable to prior published work. To minimize confusion, all results are reported with reference to the horizontal or vertical filter from which they were generated. Fractal dimensions from which the BTI parameters were extracted reflect the number, spacing, and crossconnectivity of bone trabeculae. Of the 6 BTI parameters that were extracted, we included in our analysis the parameters that have been associated with OA status and progression in previous studies (i.e., quadratic slope from the horizontal filter and vertical filter [HF and VF, respectively] data and linear slope from the HF data) (17, 18) .
Assessment of biochemical markers. Morning blood and second morning void urine specimens were collected at each visit after an overnight fast using a uniform protocol and sent to a commercial specimen repository where they were stored at 2708 C. The results of the primary, main study analyses were reported in Kraus et al (19) . For the purpose of this study, we investigated the markers involved in bone turnover, namely serum C-terminal crosslinked telopeptide of type I collagen (CTX-I), urinary CTX-Ia and CTX-Ib, urinary C-terminal crosslinked telopeptide of type II collagen (CTX-II), and serum and urinary crosslinked N-telopeptide of type I collagen (NTX-I). Interplate coefficients of variation were low (3.0% to 7.6%).
We used an interpolated value from the standard curve extended from the lowest standard to zero if the concentration of the biochemical marker was below the lower limit of detection. For urine samples, we used creatinine-adjusted values obtained by dividing the urine assay values by the corresponding creatinine result for that sample. Technical information for each of the individual assay methods can be found at https://oai.epi-ucsf.org/datarelease.
Definitions of change over time. We computed the maximum worsening in BML size scores and in osteophyte size scores across all subregions from baseline to 24 months and categorized them as, for BMLs, no change, worsening by 1 grade, or worsening by $2 grades and, for osteophytes, as no change or worsening. Within-grade changes (i.e., improvement or worsening) in BML size were also scored according to MOAKS but were not considered in this analysis. The change in total number of subregions affected by any BML (grade .0) was calculated as the difference between the number of subregions affected at 24 months and at baseline. For BMLs, this was categorized as improvement, no change, worsening by 1 subregion, or worsening by $2 subregions. The same method was used for subregions affected by any osteophyte, and the result was categorized as no change or worsening.
Changes in tAB on the medial and lateral femur and tibia and in the position on 3-dimensional shape vectors for the femur, tibia, and patella were calculated as the difference between each parameter at 24 months and baseline. TICs of BTI parameters and biochemical markers (area under the concentration versus 24-month time curve) were used to represent their change over 24 months in the longitudinal analysis.
Statistical analysis. The outcomes in our study were the structural features on bone imaging, namely the presence and change in BMLs (maximum size and number of subregions affected), subchondral BTI, vector of 3-dimensional shape, tAB, and osteophytes (maximum size and number of subregions affected). Biochemical markers were used as predictors. Continuous outcomes and biochemical marker concentrations were transposed to Z scores prior to the analysis. Age, sex, body mass index (BMI), baseline K/L grade, and use of medications with effect on bone (parathyroid hormone in the past 6 months and bisphosphonate in the past 12 months) were used as covariates. Multinomial logistic regression was used for ordinal outcomes (BMLs and osteophytes) and linear regression was used for continuous outcomes (BTI, vector of 3-dimensional shape, and bone area). Odds ratios (ORs) and 95% confidence intervals (95% CIs) for each 1 SD increase in biochemical markers were used to assess the strength of associations for BMLs and osteophytes, and partial R 2 and b (95% CIs) were used for BTI, tAB, and vector of 3-dimensional shape.
We assessed the associations between biochemical and imaging markers at baseline (cross-sectional analysis); baseline biochemical markers and changes in imaging features over 24 months (prognostic analysis); and TICs of biochemical markers over 24 months and changes in imaging features (concurrent analysis).
The diagnostic performance of biochemical markers to discriminate between knees with any BML and the ones without BMLs (binary outcome) was evaluated using receiver operating characteristic (ROC) curve analysis. P values less than 0.05 were considered statistically significant. The software used was SPSS, version 22.0.
RESULTS
The demographic characteristics of study participants and baseline concentrations of biochemical markers are shown in Table 1 . The majority of participants were women (58.8%), obese (mean BMI 30.7 kg/m 2 ), and had a K/L grade of 2 or 3 at baseline (87.5%). Baseline imaging markers and their changes over 24 months are shown in Supplementary  Table 1 (see Supplementary Table 1 , available on the Arthritis Care & Research web site at http://onlinelibrary.wiley. com/doi/10.1002/acr.23121/abstract). BMLs were found in 89% of participants at baseline, and large lesions (grade 3) were present in 18.3% of knees. Over 24 months, BMLs increased in size by 1 grade and by 2 or more grades in 45.7% and 16.6% of knees, respectively, and affected more subregions in 36.7% of knees. Osteophytes most frequently affected $6 subregions at baseline and did not change in size or number in approximately 90% of knees.
Cross-sectional analysis. The associations between biochemical and bone imaging markers at baseline are shown in Table 2 . Serum CTX-I and urinary CTX-Ia were significantly associated with large BMLs (grade 3), with the odds of a large BML being present compared to no BML increasing by 1.47-and 1.48-fold, respectively, per 1 SD increase in each biochemical marker (95% CI 1.04, 2.09 and 95% CI 1.01, 2.15, respectively). Urinary CTX-II was associated with moderate and large (grades 2 and 3) BMLs in the unadjusted analysis (results not shown) but only reached statistical significance for grade-2 BMLs (odds ratio [OR] 1.81 [95% CI 1.21, 2.74]) when covariates were added. All biochemical markers were associated with a greater number of subregions affected by any BML (4 and $5 subregions), except serum NTX-I. Levels of urinary CTX-II were additionally associated with 2 and 3 subregions affected. Excluding the BMLs that were predominantly cysts from the analyses did not significantly affect the results (data not shown).
The area under the ROC curves (AUCs), using the presence of any BML versus no BML as the outcome, indicated the best diagnostic performance for urinary CTX-II, with an AUC of 0.613 (95% CI 0.542, 0.685) before the addition of covariates and 0.688 (95% CI 0.623, 0.753) for the full model ( Figure 1 ). ROC curves using only moderate to large (grades 2 or 3) or large (grade 3) BMLs as the outcome did not yield greater AUCs (results not shown).
Urinary CTX-II was the only biochemical marker associated with osteophytes, with the odds of having a grade-3 osteophyte compared to no osteophyte increasing by 1.39-fold per 1 SD increase in urinary CTX-II (95% CI 1.10, 1.77). For BTI, baseline serum NTX-I was inversely associated with the quadratic slope from the horizontal filter data (partial R 2 0.025). With respect to bone shape, urinary CTX-II was the soluble marker most consistently associated with this feature, with statistically significant associations with the femur, tibia, and patella 3-dimensional shape vectors (partial R 2 ranging from 0.006 to 0.032). This marker, as well as serum CTX-I, were associated with tAB in all joint locations studied in the adjusted analysis (partial R 2 ranging from 0.005 to 0.009), but not in the unadjusted analysis.
Prognostic analysis: baseline biochemical markers and changes in bone imaging features over 24 months. Baseline urinary CTX-II was associated with changes in the number of subregions affected by any BML, although this association was significant both for improvement and for worsening by 2 subregions or more. There was no association between (Table 3) . Baseline values of serum NTX-I were inversely associated with TICs of the quadratic slope from the BTI horizontal filter data, while serum CTX-I was associated with TICs of the horizontal (linear slope) and vertical (quadratic slope) filter data. Changes in position of 3-dimensional shape vectors toward an OA shape were associated with higher baseline levels of urinary CTX-II for the patellar and tibial bones (highest R 2 5 0.012 [for patella]). With respect to subchondral bone area, baseline serum NTX-I was inversely associated with changes in tAB at the femur (medial and lateral) over 24 months. (Table 4) . Similarly, TIC of urinary CTX-II was positively associated with an increase in the number of subregions affected by osteophytes (1.30 [95% CI 1.00, 1.68]), and TIC of serum CTX-I was weakly associated with an increase in the size of osteophytes.
Concurrent change analysis
For variations in subchondral BTI, TICs of serum NTX-I and serum CTX-I were inversely associated with the horizontal and vertical filter data, respectively. TIC of urinary CTX-II was associated with changes in bone shape in the femur, tibia, and patella over 24 months and changed concurrently with tAB in all joint locations studied, except the lateral femur.
DISCUSSION
Both at baseline and longitudinally, we found several modest associations between collagen biochemical and bone imaging markers. In the cross-sectional analysis, higher baseline levels of most biochemical markers were associated with a greater number of subregions affected by BMLs across the whole knee; serum CTX-I and urinary CTX-Ia were also associated with larger BMLs. Fewer and less consistent associations were found for osteophytes, with only urinary CTX-II found to be associated with large osteophytes at baseline and increasing concurrently with an increasing number of subregions affected over 24 months. Serum NTX-I was consistently associated with 1 BTI parameter (quadratic slope of the horizontal filter data) both at baseline and over 24 months. Similarly, urinary CTX-II was consistently associated with 3-dimensional shape vectors in most joint locations in the cross-sectional and longitudinal analyses. In addition, higher baseline urinary CTX-II levels were associated with greater tAB in most joint locations at baseline, and their TICs were associated with increases in tAB in the concurrent analysis.
The association between urinary CTX-II and BMLs accords with findings by Garnero et al, who also demonstrated a positive association between this marker and total BML score across the knee. No such relationship was found for serum CTX-I (20) . In contrast to our investigation, in that study BML was the only bone feature examined. In addition, serum NTX-I has been weakly associated with the presence of BMLs on MRI, which was not observed in our study (21) . Ref.
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Ref. Although our main definition of BML magnitude and progression did not focus on total BML scores, we investigated whether or not summing the BML size scores across all 15 knee subregions both at baseline and at 24 months would reveal more evident associations at baseline or in BML progression. However, this approach showed similar results, with all biochemical markers, except serum NTX-I, being associated with a total BML score in the highest quartile, and with the strongest association with urinary CTX-II (OR 1.81 [95% CI 1.32, 2.50]). No additional associations were found with BML progression. Consistent with our findings, another study has shown that total osteophyte score, defined by the sum of osteophyte sizes in each knee compartment, was independently associated with baseline urinary CTX-II (a molecular marker of collagen type II degradation) but not with baseline urinary CTX-Ia (22) . This association with urinary CTX-II may be consistent with the endochondral ossification related to osteophyte formation, including expression of type II collagen in a cartilage anlage, with subsequent replacement by bone (23, 24) .
Recent studies, however, have found that urinary CTX-II is often associated with changes in bone on imaging, as well as with other soluble markers of bone remodeling (22, 25) . In our study, this marker was frequently associated with most of the bone imaging features investigated. CTX-II has been detected in the bone-cartilage interface (26) , and it has been suspected that its origin is more related to bone than cartilage (25) . Interestingly, there is evidence that type II collagen and type II collagen metabolism are involved in bone marrowderived mesenchymal stem cell osteogenesis during bone remodeling and repair (27) .
In the longitudinal analysis using either baseline or TIC values of biochemical markers, we found fewer significant associations for changes in BMLs and osteophytes over 24 months. Only a few studies have investigated this association longitudinally. Garnero et al showed a significant association between levels of urinary CTX-II in the highest tertile and worsening in BMLs after 3 months (relative risk 2.4 [95% CI 1.1, 5.0]) (20) . In another study, urinary CTX-II and urinary CTX-Ia at baseline were predictive of osteophyte progression after 3 years (P 5 0.0001 and P 5 0.01, respectively) (22) . In our study, urinary CTX-II was not predictive of worsening in osteophyte number or size but changed concurrently with its progression over 24 months.
Previous work demonstrated that lower vertical filter data of BTI, representing thickened horizontal trabeculae, was associated with a higher risk of OA progression (17) . We found that, in the concurrent analysis, the quadratic slope of the vertical filter data decreased concurrently with an increase in serum CTX-I levels, although this association was weak. Furthermore, serum NTX-I was consistently associated with the horizontal filter data (vertical trabeculae) at baseline and over 24 months (inverse associations). Changes in BTI of the horizontal filter data were shown to be modestly associated with concurrent changes in both radiographic and MRI parameters of OA progression (18) . Higher horizontal filter data represents thinning of vertical trabeculae and, in our study, this was associated with lower serum NTX-I levels. Variations in BTI probably occur due to altered subchondral bone turnover, which is reflected, in our study, by the significant associations with several markers of bone remodeling (baseline and TICs).
Three-dimensional bone shape has been shown to identify knees at increased risk for incident radiographic OA (14) . Moreover, results from the NIH biomarkers study showed that changes in bone shape and area over 24 months were predictive of clinical and radiographic progression over 48 months (16) . There is a lack of studies determining their association with biochemical markers involved in bone remodeling, and we showed that they were consistently associated with urinary CTX-II, particularly in the crosssectional evaluation.
Our analyses were performed both with and without the inclusion of covariates, including age, sex, BMI, and K/L grade. It has been demonstrated that these demographic features and K/L grade may affect bone biochemical markers levels (28) (29) (30) (31) . Moreover, they were often independently associated with the imaging markers in our study. It supports the idea that these covariates may act as confounders in the association between bone biochemical markers and imaging features. We observed a considerable increase in the AUCs after the inclusion of the covariates, although most of the associations found were present in both the unadjusted and adjusted analyses.
There are several limitations to our study. First, we have performed a post hoc analysis of the Foundation for the NIH Biomarkers Consortium OA study, which was selected to include one-quarter OA progressors (both clinical and radiographic progression), one-quarter nonprogressors, and onehalf either clinical-only or radiographic-only progressors. Case-control status has not been considered in our analysis, and whether or not associations would be different in an unselected OA population with different rates of progression (e.g., the general knee OA population) is unclear. Second, we did not adjust for menopausal status, which is known to interfere with biochemical markers of bone turnover. However, the female population studied is comprised predominantly of postmenopausal women (86.6%), so it is unlikely that it would change the associations found. Third, we did not have data on bone mineral density of participants to use as a covariate, which can influence the levels of biochemical markers of bone turnover. Finally, no adjustment was made for multiple comparisons, so the presence of type I error cannot be ruled out.
In conclusion, despite several statistically significant associations, the practical utility of these systemic biochemical markers by themselves as predictors of these anatomic bone features of individual knees seems limited due to the modest strength of most of the associations.
